The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis

被引:49
|
作者
Tehranian, Cedric [1 ]
Fankhauser, Laura [1 ]
Harter, Patrick N. [2 ,3 ,4 ]
Ratcliffe, Colin D. H. [5 ]
Zeiner, Pia S. [2 ,4 ,6 ]
Messmer, Julia M. [1 ,7 ]
Hoffmann, Dirk C. [1 ,7 ]
Frey, Katharina [1 ]
Westphal, Dana [8 ,9 ]
Ronellenfitsch, Michael W. [4 ,6 ]
Sahai, Erik [5 ]
Wick, Wolfgang [1 ,2 ]
Karreman, Matthia A. [1 ,2 ]
Winkler, Frank [1 ,2 ]
机构
[1] German Canc Res Ctr, Clin Cooperat Unit Neurooncol, German Canc Consortium DKTK, INF 280, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Neurol Clin & Natl Ctr Tumor Dis, Heidelberg, Germany
[3] Univ Frankfurt Main, Edinger Inst, Inst Neurol, Frankfurt, Germany
[4] Frankfurt Canc Inst FCI, Frankfurt, Germany
[5] Francis Crick Inst, Tumour Cell Biol Lab, London, England
[6] Univ Frankfurt Main, Senckenberg Inst Neurooncol, Frankfurt, Germany
[7] Heidelberg Univ, Fac Biosci, Heidelberg, Germany
[8] Tech Univ Dresden, Dept Dermatol, Med Fac, Dresden, Germany
[9] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany
基金
英国惠康基金; 英国医学研究理事会;
关键词
brain metastasis; dual PI3K; mTOR inhibition; extravasation; PI3K; Akt; mTOR pathway; tertiary prevention; PI3K PATHWAY; BREAST-CANCER; GROWTH; SURVIVAL; EFFICACY; THERAPY; REVEALS; CROSS;
D O I
10.1093/neuonc/noab159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Brain metastases (BM) are a frequent complication of malignant melanoma (MM), with limited treatment options and poor survival. Prevention of BM could be more effective and better tolerated than treating established BM in various conditions. Methods To investigate the temporospatial dynamics of PI3K/Akt/mTOR (PAM) pathway activation during BM formation and the preventive potential of its inhibition, in vivo molecular imaging with an Akt biosensor was performed, and long-term intravital multiphoton microscopy through a chronic cranial window in mice. Results In vivo molecular imaging revealed invariable PAM pathway activation during the earliest steps of brain colonization. In order to perform a long-term intravascular arrest and to extravasate, circulating MM cells needed to activate their PAM pathway during this process. However, the PAM pathway was quite heterogeneously activated in established human brain metastases, and its inhibition with the brain-penetrant PAM inhibitor GNE-317 resulted in only modest therapeutic effects in mice. In contrast, giving GNE-317 in preventive schedules that included very low doses effectively reduced the growth rate and number of BM in two MM mouse models over time, and led to an overall survival benefit. Longitudinal intravital multiphoton microscopy found that the first, rate-limiting steps of BM formation-permanent intravascular arrest, extravasation, and initial perivascular growth-are most vulnerable to dual PI3K/mTOR inhibition. Conclusion These findings establish a key role of PAM pathway activation for critical steps of early metastatic brain colonization and reveal its pharmacological inhibition as a potent avenue to prevent the formation of clinically relevant BM.
引用
收藏
页码:213 / 225
页数:13
相关论文
共 50 条
  • [21] A Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
    Totiger, T.
    Srinivasan, S.
    Jala, V.
    Castellanos, J.
    Lamichhane, P.
    Dai, X.
    Vansaun, M.
    Merchant, N.
    Nagathihalli, N.
    PANCREAS, 2017, 46 (10) : 1440 - 1440
  • [22] The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
    Basile, Maria Sofia
    Cavalli, Eugenio
    McCubrey, James
    Hernandez-Bello, Jorge
    Munoz-Valle, Jose Francisco
    Fagone, Paolo
    Nicoletti, Ferdinando
    DRUG DISCOVERY TODAY, 2022, 27 (03) : 848 - 856
  • [23] Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
    Pavlidou, Athanasia
    Vlahos, Nikos F.
    SCIENTIFIC WORLD JOURNAL, 2014,
  • [24] The PI3K-AKT pathway - a therapeutic target in melanoma brain metastases?
    Niessner, H.
    Schmitz, J.
    Schmid, A.
    Sinnberg, T.
    Tabatabai, G.
    Weide, B.
    Garbe, C.
    Quintanilla-Fend, L.
    Mai, M.
    Beissert, S.
    Kulms, D.
    Schackert, G.
    Muders, M.
    Meinhardt, M.
    Baretton, G.
    Pichler, B.
    Westphal, D.
    Meier, F.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E35 - E35
  • [25] Targeting the PI3K/Akt/mTOR Pathway in Ocular Neovascularization
    Sasore, Temitope
    Reynolds, Alison L.
    Kennedy, Breandan N.
    RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2014, 801 : 805 - 811
  • [26] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [27] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [28] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [29] Evaluation of the PI3K/AKT/mTOR pathway in multiple sclerosis
    Mammana, Santa
    Fagone, Paolo
    Cavalli, Eugenio
    Basile, Maria Sofia
    Petralia, Maria Cristina
    Nicoletti, Ferdinando
    Mangano, Katia
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S51 - S51
  • [30] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
    Markman, Ben
    Dienstmann, Rodrigo
    Tabernero, Josep
    ONCOTARGET, 2010, 1 (07) : 530 - 543